Print Page
Recommend Page

Contact

Dr. James Adjaye

Max Planck Institute for Molecular Genetics, Berlin

Phone: +49 30 8413-1203

Email: adjaye@­molgen.mpg.de

Dr. Alessandro Prigione

Max Planck Institute for Molecular Genetics, Berlin

Phone: +49 30 8413-1237
Fax: +49 30 8413-1128

Email: prigione@­molgen.mpg.de

Original publication

Alessandro Prigione, Björn Lichtner, Heiner Kuhl, Eduard A. Struys, Mirjam Wamelink, Hans Lehrach, Markus Ralser, Bernd Timmermann, James Adjaye
Human Induced Pluripotent Stem Cells Harbor Homoplasmic and Heteroplasmic Mitochondrial DNA Mutations while Maintaining Human Embryonic Stem Cell-Like Metabolic Reprogramming
Stem Cells, 5 July 2011, doi: 10.1002/stem.683

Cell Biology . Genetics . Medicine

Mitochondrial genome mutates when reprogrammed

Max Planck researchers encounter genetic changes in the genome of the cellular power plants of human induced pluripotent stem cells

July 28, 2011

Induced pluripotent stem cells (iPS cells) are truly talented multi-taskers. They can reproduce almost all cell types and thus offer great hope in the fight against diseases like Alzheimer’s and Parkinson’s. However, it would appear that their use is not entirely without risk: during the reprogramming of body cells into iPS cells, disease-causing mutations can creep into the genetic material. The genome of the mitochondria – the cell’s protein factories – is particularly vulnerable to such changes. This phenomenon has been discovered by researchers at the Max Planck Institute for Molecular Genetics in Berlin. The scientists encountered mutations in the mitochondrial genome of iPS cells. Because such genetic mutations can cause diseases, the cells should be tested for such mutations before being used for clinical applications.
standard Zoom Image
Mutations in the mitochondrial genome of iPS cells
© MPI for Molecular Genetics

A lot of hope is riding on induced pluripotent stem cells (iPS cells). Because they can be generated individually for every single person, they are expected to enable the development of tailor-made therapies that do not run the risk of triggering rejection reactions. iPS cells also offer a promising solution for drug screening, as researchers can generate different cell  types such as liver cells from them, on which they can then test the effect of substances. iPS cells can be generated from adult body cells using the technique of “cellular reprogramming”. The method raises no ethical concerns as it does not involve the destruction of embryos.

However, these promising cells are also associated with certain risks. Disease-causing mutations can also arise during the reprogramming of the body cells. The genetic material in the mitochondria is particularly vulnerable to changes in the genetic code. The question as to whether such mutations arise as a result of the reprogramming process had not previously been investigated.

A cooperative research study involving two research groups from the Max Planck Institute for Molecular Genetics in Berlin has now carried out a search for mutations in the mitochondrial genome of iPS cells. James Adjaye’s research group recently discovered that the mitochondria rejuvenate in the course of reprogramming. Working in cooperation with Bernd Timmermann’s Next Generation Sequencing research group, Adjaye’s team has succeeded in showing that genetic mutations exist in the mitochondrial genome of all reprogrammed cells that were not present in the original cells. The amount of mutations varies significantly between the individual iPS cells examined. In all cases, the changes did not involve large-scale rearrangements but rather modifications of single letters in the genetic code.

 
/4382218/ips_cell_mutations
loading content